Inovio Pharmaceuticals (Formerly Known as Inovio Biomedical Corporation) Awarded Follow-on Funding from the PATH Malaria Vaccine Initiative for DNA Vaccine Development

BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the PATH Malaria Vaccine Initiative (MVI) has agreed to provide follow-on funding to continue evaluation and development of Inovio’s malaria DNA vaccine candidate in non-human primates.